<p>根据波士顿合伙人最近向美国证券交易委员会（SEC）披露的信息，波士顿合伙人在 2023 年第四季度将其在 IQVIA Holdings Inc.（纽约证券交易所代码：IQV - 免费报告）的股份增加了 14.9%。该机构投资者在此期间额外购买了 530,672 股后，持有该医疗研究公司 4,087,380 股股票。IQVIA 大约占波士顿合伙人投资组合的 1.0%，使其成为该投资组合中第 14 大持仓。截至最近向 SEC 提交的文件，波士顿合伙人持有的 IQVIA 股份约占 2.40%，价值 923,276,000 美元。</p>
<ul>
<li>超越生物科技——3 只适合成长型投资者的医疗股票</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也增加或减少了对该股票的持仓。Eagle Rock Investment Company LLC 在第三季度将其在 IQVIA 的持股增加了 33.6%。Eagle Rock Investment Company LLC 目前持有 46,332 股该医疗研究公司的股票，价值 8,800,000 美元，此前在此期间又购买了 11,657 股。EDENTREE ASSET MANAGEMENT Ltd 在第三季度购买了价值约 7,368,000 美元的 IQVIA 新头寸。AMG National Trust Bank 在第三季度购买了价值约 3,713,000 美元的 IQVIA 新头寸。花旗集团在第三季度将其在 IQVIA 的持股增加了 108.2%。花旗集团目前持有 915,183 股该医疗研究公司的股票，价值 173,830,000 美元，此前在上个季度又购买了 475,557 股。最后，Dana Investment Advisors Inc.在第三季度将其在 IQVIA 的持股增加了 18.4%。Dana Investment Advisors Inc.目前持有 160,057 股该医疗研究公司的股票，价值 30,401,000 美元，此前在上个季度又购买了 24,854 股。目前 89.62% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师观点</h2>
<p>IQVIA 已经成为多份研究报告的主题。摩根士丹利在 5 月 7 日的研究报告中对 IQVIA 的股票设定了 225.00 美元的目标价。Evercore 在 4 月 8 日的研究报告中重申了对 IQVIA 的 “跑赢大盘” 评级，并设定了 185.00 美元的目标价。Wall Street Zen 在 6 月 6 日的研究报告中将 IQVIA 的股票评级从 “买入” 下调至 “持有”。TD Cowen 在 3 月 9 日的研究报告中将 IQVIA 的股票评级从 “持有” 上调至 “买入”，并将该公司的目标价从 174.00 美元上调至 213.00 美元。最后，瑞穗在 2 月 23 日的报告中对 IQVIA 设定了 215.00 美元的目标价。两位股票研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，两位给予了持有评级。根据 MarketBeat 的数据，IQVIA 目前的平均评级为 “买入”，共识目标价为 224.13 美元。</p>
<p><strong>阅读我们对 IQV 的最新分析</strong></p>
<h2>IQVIA 股票表现</h2>
<p>IQVIA 股票在周五开盘价为 181.10 美元。该公司的 50 日移动平均价格为 173.56 美元，200 日移动平均价格为 193.68 美元。IQVIA Holdings Inc.的 12 个月低点为 153.01 美元，12 个月高点为 247.04 美元。该公司的速动比率为 0.75，流动比率为 0.75，债务股本比率为 2.20。该公司的市值为 302.3 亿美元，市盈率为 22.44，市盈率增长比率为 1.55，贝塔值为 1.21。</p>
<p>IQVIA（纽约证券交易所代码：IQV - 获取免费报告）最近在 5 月 5 日发布了其财报。该医疗研究公司报告本季度每股收益为 2.90 美元，超出分析师一致预期的 2.83 美元，超出幅度为 0.07 美元。IQVIA 的净利润率为 8.33%，股本回报率为 30.50%。该公司本季度的收入为 41.5 亿美元，而一致预期为 41 亿美元。在去年同期，该公司每股收益为 2.70 美元。该公司的季度收入同比增长 8.4%。IQVIA 已将其 2026 财年的指引设定为每股收益 12.650-12.950 美元。平均而言，股票研究分析师预测 IQVIA Holdings Inc.在当前财年将发布每股收益 11.6 美元。</p>
<p>IQVIA 宣布其董事会在 5 月 7 日启动了一项股票回购计划，授权公司回购 20 亿美元的股份。该回购授权允许该医疗研究公司通过公开市场购买最多 6.8% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>关于 IQVIA</h2>
<p>（免费报告）</p>
<p>IQVIA NYSE: IQV 是生命科学行业先进分析、技术解决方案和合同研究服务的全球提供商。该公司将临床研究能力与大规模健康数据和分析相结合，以支持药物开发、监管报告、商业战略和真实世界证据生成。IQVIA 的当前形式源于 2016 年宣布的 Quintiles 与 IMS Health 的合并，随后重新品牌为 IQVIA，结合了长期建立的临床研究运营和广泛的医疗信息资产。</p>
<p>IQVIA 的主要活动包括外包临床开发服务（作为 I-IV 期的合同研究组织）、真实世界证据和观察性研究、监管和安全服务，以及一系列技术平台，支持数据集成、分析和运营管理。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票超过 IQVIA</li>
<li>SpaceX 敲响钟声，打破所有记录</li>
<li>Adobe 股票刚刚变便宜——华尔街是否忽视了这个故事？</li>
<li>3 只股息股票低于 50 美元，支付你等待通货膨胀的费用</li>
<li>127 吉瓦问题：为什么人工智能需要自己的电力</li>
</ul>
<p><strong>想看看其他对冲基金持有的 IQV 吗？</strong> 访问 HoldingsChannel.com 获取 IQVIA Holdings Inc.（纽约证券交易所代码：IQV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1JUVY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1JUVY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 IQVIA 吗？</h2>
<p>在考虑 IQVIA 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意之前购买的股票……而 IQVIA 并不在名单上。</p>
<p>虽然 IQVIA 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

花旗

<p>波士顿合伙公司在第四季度将其在 IQVIA Holdings Inc.的持股增加了 14.9%，收购了 530,672 股，总持股达到 4,087,380 股，估值约为 9.23 亿美元。其他机构投资者如 Eagle Rock 和花旗也增加了他们的持股。同时，华尔街分析师维持了一致的 “买入” 评级，平均目标价为 224.13 美元，尽管摩根士丹利和 TD Cowen 等公司的近期评级变化不一</p>

<p>Boston Partners increased its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 14.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,087,380 shares of the medical research company's stock after acquiring an additional 530,672 shares during the period. IQVIA comprises approximately 1.0% of Boston Partners' portfolio, making the stock its 14th largest position. Boston Partners owned about 2.40% of IQVIA worth $923,276,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>根据波士顿合伙人最近向美国证券交易委员会（SEC）披露的信息，波士顿合伙人在 2023 年第四季度将其在 IQVIA Holdings Inc.（纽约证券交易所代码：IQV - 免费报告）的股份增加了 14.9%。该机构投资者在此期间额外购买了 530,672 股后，持有该医疗研究公司 4,087,380 股股票。IQVIA 大约占波士顿合伙人投资组合的 1.0%，使其成为该投资组合中第 14 大持仓。截至最近向 SEC 提交的文件，波士顿合伙人持有的 IQVIA 股份约占 2.40%，价值 923,276,000 美元。</p>
</div><ul>
<li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>超越生物科技——3 只适合成长型投资者的医疗股票</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Eagle Rock Investment Company LLC boosted its holdings in shares of IQVIA by 33.6% during the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company's stock worth $8,800,000 after purchasing an additional 11,657 shares during the period. EDENTREE ASSET MANAGEMENT Ltd bought a new position in IQVIA in the third quarter worth about $7,368,000. AMG National Trust Bank bought a new position in IQVIA in the third quarter worth about $3,713,000. Citigroup Inc. raised its stake in IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company's stock worth $173,830,000 after buying an additional 475,557 shares in the last quarter. Finally, Dana Investment Advisors Inc. raised its stake in IQVIA by 18.4% in the third quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company's stock worth $30,401,000 after buying an additional 24,854 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也增加或减少了对该股票的持仓。Eagle Rock Investment Company LLC 在第三季度将其在 IQVIA 的持股增加了 33.6%。Eagle Rock Investment Company LLC 目前持有 46,332 股该医疗研究公司的股票，价值 8,800,000 美元，此前在此期间又购买了 11,657 股。EDENTREE ASSET MANAGEMENT Ltd 在第三季度购买了价值约 7,368,000 美元的 IQVIA 新头寸。AMG National Trust Bank 在第三季度购买了价值约 3,713,000 美元的 IQVIA 新头寸。花旗集团在第三季度将其在 IQVIA 的持股增加了 108.2%。花旗集团目前持有 915,183 股该医疗研究公司的股票，价值 173,830,000 美元，此前在上个季度又购买了 475,557 股。最后，Dana Investment Advisors Inc.在第三季度将其在 IQVIA 的持股增加了 18.4%。Dana Investment Advisors Inc.目前持有 160,057 股该医疗研究公司的股票，价值 30,401,000 美元，此前在上个季度又购买了 24,854 股。目前 89.62% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>IQV has been the subject of a number of research reports. Morgan Stanley set a $225.00 price target on shares of IQVIA in a research note on Thursday, May 7th. Evercore reaffirmed an &#34;outperform&#34; rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Wall Street Zen downgraded shares of IQVIA from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, June 6th. TD Cowen raised shares of IQVIA from a &#34;hold&#34; rating to a &#34;buy&#34; rating and raised their target price for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Mizuho set a $215.00 price target on shares of IQVIA in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of &#34;Buy&#34; and a consensus price target of $224.13.</p>
<div class="lb-trans"><p>IQVIA 已经成为多份研究报告的主题。摩根士丹利在 5 月 7 日的研究报告中对 IQVIA 的股票设定了 225.00 美元的目标价。Evercore 在 4 月 8 日的研究报告中重申了对 IQVIA 的 “跑赢大盘” 评级，并设定了 185.00 美元的目标价。Wall Street Zen 在 6 月 6 日的研究报告中将 IQVIA 的股票评级从 “买入” 下调至 “持有”。TD Cowen 在 3 月 9 日的研究报告中将 IQVIA 的股票评级从 “持有” 上调至 “买入”，并将该公司的目标价从 174.00 美元上调至 213.00 美元。最后，瑞穗在 2 月 23 日的报告中对 IQVIA 设定了 215.00 美元的目标价。两位股票研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，两位给予了持有评级。根据 MarketBeat 的数据，IQVIA 目前的平均评级为 “买入”，共识目标价为 224.13 美元。</p>
</div><p><strong>Read Our Latest Analysis on IQV</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 IQV 的最新分析</strong></p>
</div><h2>IQVIA Stock Performance</h2>
<div class="lb-trans"><h2>IQVIA 股票表现</h2>
</div><p>IQVIA stock opened at $181.10 on Friday. The company's 50-day moving average price is $173.56 and its 200-day moving average price is $193.68. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market cap of $30.23 billion, a PE ratio of 22.44, a price-to-earnings-growth ratio of 1.55 and a beta of 1.21.</p>
<div class="lb-trans"><p>IQVIA 股票在周五开盘价为 181.10 美元。该公司的 50 日移动平均价格为 173.56 美元，200 日移动平均价格为 193.68 美元。IQVIA Holdings Inc.的 12 个月低点为 153.01 美元，12 个月高点为 247.04 美元。该公司的速动比率为 0.75，流动比率为 0.75，债务股本比率为 2.20。该公司的市值为 302.3 亿美元，市盈率为 22.44，市盈率增长比率为 1.55，贝塔值为 1.21。</p>
</div><p>IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the firm posted $2.70 EPS. The business's quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>IQVIA（纽约证券交易所代码：IQV - 获取免费报告）最近在 5 月 5 日发布了其财报。该医疗研究公司报告本季度每股收益为 2.90 美元，超出分析师一致预期的 2.83 美元，超出幅度为 0.07 美元。IQVIA 的净利润率为 8.33%，股本回报率为 30.50%。该公司本季度的收入为 41.5 亿美元，而一致预期为 41 亿美元。在去年同期，该公司每股收益为 2.70 美元。该公司的季度收入同比增长 8.4%。IQVIA 已将其 2026 财年的指引设定为每股收益 12.650-12.950 美元。平均而言，股票研究分析师预测 IQVIA Holdings Inc.在当前财年将发布每股收益 11.6 美元。</p>
</div><p>IQVIA announced that its board has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its shares are undervalued.</p>
<div class="lb-trans"><p>IQVIA 宣布其董事会在 5 月 7 日启动了一项股票回购计划，授权公司回购 20 亿美元的股份。该回购授权允许该医疗研究公司通过公开市场购买最多 6.8% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>About IQVIA</h2>
<div class="lb-trans"><h2>关于 IQVIA</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.</p>
<div class="lb-trans"><p>IQVIA NYSE: IQV 是生命科学行业先进分析、技术解决方案和合同研究服务的全球提供商。该公司将临床研究能力与大规模健康数据和分析相结合，以支持药物开发、监管报告、商业战略和真实世界证据生成。IQVIA 的当前形式源于 2016 年宣布的 Quintiles 与 IMS Health 的合并，随后重新品牌为 IQVIA，结合了长期建立的临床研究运营和广泛的医疗信息资产。</p>
</div><p>IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.</p>
<div class="lb-trans"><p>IQVIA 的主要活动包括外包临床开发服务（作为 I-IV 期的合同研究组织）、真实世界证据和观察性研究、监管和安全服务，以及一系列技术平台，支持数据集成、分析和运营管理。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than IQVIA</li>
<li>SpaceX Rings the Bell and Shatters Every Record</li>
<li>Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?</li>
<li>3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation</li>
<li>The 127-Gigawatt Problem: Why AI Needs Its Own Power</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 IQVIA</li>
<li>SpaceX 敲响钟声，打破所有记录</li>
<li>Adobe 股票刚刚变便宜——华尔街是否忽视了这个故事？</li>
<li>3 只股息股票低于 50 美元，支付你等待通货膨胀的费用</li>
<li>127 吉瓦问题：为什么人工智能需要自己的电力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding IQV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 IQV 吗？</strong> 访问 HoldingsChannel.com 获取 IQVIA Holdings Inc.（纽约证券交易所代码：IQV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=IQV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in IQVIA Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 IQVIA 吗？</h2>
</div><p>Before you consider IQVIA, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 IQVIA 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意之前购买的股票……而 IQVIA 并不在名单上。</p>
</div><p>While IQVIA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IQVIA 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Boston Partners Purchases 530,672 Shares of IQVIA Holdings Inc. $IQV

Market Beat

IQVIA

Toronto Dominion Bank

摩根士丹利

Evercore

瑞穗金融集团

Mizuho Financial Group, Inc.

CITIGROUP INC 6.250 NON CUM SER II PFD WI

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

波士顿合伙人购入了 530,672 股 IQVIA Holdings Inc.的股票